ArticleCureus2026
Hepatitis B Virus Reactivation During Rituximab Therapy Despite Anti-HBs Positivity: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) reactivation is a well-recognized complication of immunosuppressive therapy, particularly with B-cell-depleting agents such as rituximab. Anti-HBs positivity may reflect previous immune control, but it does not eliminate the risk of reactivation in patients with previously resolved HBV infection. We report the case of a 63-year-old man with splenic marginal zone lymphoma treated with rituximab-based chemotherapy. Before treatment, HBV testing showed negative HBsAg, positive anti-HBc, positive anti-HBs, and undetectable HBV DNA. No antiviral prophylaxis was initiated before chemotherapy, although the patient was retrospectively considered at high risk for HBV reactivation because of anti-HBc positivity and planned rituximab therapy. Approximately two months after the last chemotherapy cycle, he developed marked hepatic cytolysis. Further evaluation showed new HBsAg positivity, persistent anti-HBs positivity, and detectable HBV DNA, confirming HBV reactivation with HBsAg seroreversion. Tenofovir disoproxil fumarate was started, resulting in normalization of liver enzymes and sustained virological suppression. This case emphasizes that anti-HBs positivity should not be considered sufficient protection against HBV reactivation in patients receiving rituximab. Systematic HBV screening, guideline-based antiviral prophylaxis in high-risk patients, and prolonged virological monitoring are essential to prevent severe hepatic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.